CoChat

Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease

The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators · 2005 · New England Journal of Medicine

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Prophylactic transfusion prevents strokes in children with sickle cell anemia who have abnormalities on transcranial Doppler ultrasonographic examination. However, it is not known how long transfusion should be continued in these children. METHODS: We studied children with sickle cell disease who had a high risk of stroke on the basis of a transcranial Doppler screening examination and who had received transfusions for 30 months or longer, during which time the Doppler readings became normal. The children were randomly assigned to continued transfusion or no continued transfusion. Children with severe stenotic lesions on cerebral magnetic resonance angiography were excluded. The composite primary end point was stroke or reversion to a result on Doppler examination indicative of a high risk of stroke. RESULTS: The study was stopped after 79 children of a planned enrollment of 100 underwent randomization. Among the 41 children in the transfusion-halted group, high-risk Doppler results developed in 14 and stroke in 2 others within a mean (+/-SD) of 4.5+/-2.6 months (range, 2.1 to 10.1) of the last transfusion. Neither of these events of the composite end point occurred in the 38 children who continued to receive transfusions. The average of the last two transcranial Doppler results before transfusion was started was the only predictor of the composite end point (P=0.05). CONCLUSIONS: Discontinuation of transfusion for the prevention of stroke in children with sickle cell disease results in a high rate of reversion to abnormal blood-flow velocities on Doppler studies and stroke. (ClinicalTrials.gov number, NCT00006182.)

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa050460

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Ohene-Frempong K, 1998, Blood, 91, 288
  2. Walters MC, 2000, Blood, 95, 1918

Cited by

See all 665

Metadata

Authors
The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators
Affiliations
Augusta University (US)
Corresponding author
The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators
Venue
New England Journal of Medicine
Published
2005-12-29
Volume
353
Issue
26
Pages
2769-2778
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1498156640
Cited by
635
References
27
Citations by year
2026: 23 · 2025: 12 · 2024: 31 · 2023: 22 · 2022: 29 · 2021: 27 · 2020: 34 · 2019: 25 · 2018: 35 · 2017: 37 · 2016: 43 · 2015: 25 · 2014: 32 · 2013: 32 · 2012: 45
FWCI
12.21
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (U01HL052193, U01HL052016)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Blood transfusion and management
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
Keywords
sickle cell disease, stroke prevention, prophylactic transfusion, transcranial Doppler screening, cerebral blood flow velocity, children
MeSH terms
Adolescent, Adult, Anemia, Sickle Cell, Blood Flow Velocity, Blood Transfusion, Brain, Child, Female, Humans, Magnetic Resonance Imaging, Male, Risk, Chelation Therapy, Ultrasonography, Doppler, Transcranial, Stroke, Middle Cerebral Artery, Withholding Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.